Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP28 | Q96RU2 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | PDCD1 | Q15116 | 4/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 4/20 | 0.38 |
| ▸ | USP25 | Q9UHP3 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | PNP | P00491 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.34 |
| ▸ | FEN1 | P39748 | 1/20 | 0.34 |
| ▸ | STAT3 | P40763 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL594696 | 0.84 | MAOA (0.33) | KMT2A | |
| SCHEMBL594426 | 0.80 | CA2 (0.34) | — | |
| SCHEMBL3635441 | 0.78 | IDO1 (0.30) | — | |
| SCHEMBL393029 | 0.77 | PDXK (0.33) | KMT2AMEN1ALDH1A1LMNA | |
| SCHEMBL30570456 | 0.76 | SLC6A4 (0.38) | PDCD1CD274ALDH1A1CYP2D6 | |
| SCHEMBL1338930 | 0.76 | SLC6A4 (0.38) | PDCD1CD274ALDH1A1CYP2D6 | |
| SCHEMBL594259 | 0.73 | GAA (0.36) | KMT2ASMN1; SMN2MEN1MAPK1ALDH1A1 | |
| SCHEMBL593789 | 0.72 | SLC2A1 (0.34) | ALDH1A1 | |
| SCHEMBL392361 | 0.71 | — | — | |
| SCHEMBL594666 | 0.71 | APP (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101568539-B | Imidazolidinonyl aminopyrimidine compounds for the treatment of cancer | LILLY CO ELI | 2012-04-25 | — | — | CN | disclosed |
| US-8114872-B2 | Triazolyl aminopyrimidine compounds | ELI LILLY AND COMPANY (US) | 2012-02-14 | — | — | US | disclosed |
| EP-2125794-B1 | IMIDAZOLIDINONYL AMINOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | LILLY CO ELI (US) | 2010-10-20 | — | — | EP | disclosed |
| US-20100130466-A1 | TRIAZOLYL AMINOPYRIMIDINE COMPOUNDS | ELI LILLY AND COMPANY | 2010-05-27 | — | — | US | disclosed |
| CN-101568539-A | Imidazolidinonyl aminopyrimidine compounds for the treatment of cancer | LILLY CO ELI (US) | 2009-10-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130466-A1 | TRIAZOLYL AMINOPYRIMIDINE COMPOUNDS | DPYD, TP53, TYMP | USP28 3755/4885KMT2A 1133/4885SMN1; SMN2 3333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.